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Preliminary screening for in vitro cytotoxic and inhibition nitric oxide (NO) production 
acivities were  carried out on fourteen extracts of different parts of eight Garcinia 
species. These extracts were evaluated for cytotoxic activity using microculture 
tetrazolium, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
by measuring the reduction of viability of cell cultures in the presence and absence of 
the extracts. Four type of cancer cell lines, HL-60 (leukemia), MCF-7 (breast), DU-145 
(prostate) and NCI-H460 (non-small cell lung) were used for a preliminary picture of 
extracts selectivity profile. NO inhibition (in lipopolysaccharide (LPS)-activated 
macrophages) activity was evaluated using Griess assay.  
 
Extract of the stem bark from G. cowa Roxb showed selective cytotoxicity towards NCI-
H460 (IC50 = 11 µg/mL). The extract also exhibited inhibition of NO production (IC50= 
 iv
25 µg/mL) without being cytotoxic to RAW 264.7 cells. Based on these promising 
selective cytotoxicity towards NCI-H460 and NO inhibitory activities, G. cowa was 
selected for further studies on the isolation and identification its active components. 
 
Bioassay-guided isolation of the stem extracts, yielded seven cytotoxic compounds. 
Utilising various spectroscopic (EI-MS, UV, IR, NMR and HRMS) analyses, three of 
them were identified as new compounds and characterized as [2E,6E,10E]-(+)-4β-
hydroxy-3-methyl-5β-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl-2-
cyclohexen-1-one (85), 2-(3-methyl-2-butenyl)-1,5,6-trihydroxy-3-methoxy-4-(1,1-
dimethyl-2-propenyl)-9H-xanthen-9-one (87) and 1,3,6-trihydroxy-7-methoxy-4-(4-
acetoxy-3-methyl-2-butenyl)-8-(3,7-dimethyl-2,6-octadienyl)xanthone (88). Four other 
known compounds were elucidated on the basis of their spectroscopy data and 
comparison with the literature. They were identified as rubraxanthone (5), cowanin (52), 
α-mangostin (81) and hydroxycalabaxanthone (86). Three compounds isolated from 
leaves of  G. cowa including methyl 2,4,6-trihydroxy-3-(3-methylbut-2-enyl)benzoate 
(89), garcinisidone-A (90) and 3-(1-methoxycarbonyl-4,6-dihydroxyphenoxy)-6-
methoxy-5,5-dimethyl-2-butenyl)-1,4-benzoquinone (91). Compounds 89 and 91 were 
identified as new compounds. In addition, rubraxanthone (5) and cowanin (52) were 
reisolated from roots of this plant together with 1,5-dihydroxyxanthone (92).  
 
Compounds 81, 86, 87, 88, 89, 90 and 91 exhibited moderate to strong cytotoxic activity 
on tested cells. However, only compound 85 showed selectivity towards NCI-H460 cell 
 v
line with IC50 value of 16.3 µM ± 3.0. The effect of compound 85 on the cell cycle 
progression of NCI-H460 cells was evaluated by using a flow cytometer. Compound 85 
was found to significantly arrest cells growing, predominantly in the G1 phase. 
Furthermore, compound 85 was subjected to in vivo antitumor assay on NCI-H460 
xenografted nude mice. Interestingly, compound 85 slowed the tumor growth by 5 days.  
 
Compound 85 was subjected to Griess assay along with rubraxanthone (5) and α-
mangostin (81). It was realised that the inhibition of NO production by compound 85 
was most likely due to their cytotoxicity,  with % inhibition of NO production value of 
81% and 40% of cell viability. However, inhibition of NO production by α-mangostin 
81 is high with 83% inhibition and 82% cell viabiliy. Rubraxanthone 5 showed weak 
inhibition of NO production with 24% inhibition value and 77% of cell viability.  
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Kajian awal terhadap aktiviti sitotoksik dan perencatan penghasilan nitrik oksida (NO) 
telah dilakukan ke atas 14 ekstrak pelbagai bahagian dari lapan Garcinia spesies. Eksrak 
ini diuji aktiviti sitotoksiknya dengan kaedah 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay. Barisan sel kanser, HL-60 (leukemia), MCF-7 
(kanser  payudara), DU-145 (prostat) dan NCI-H460 (paru-paru) dipakai untuk kajian 
sitotoksik ekstrak. Kaedah Griess digunakan untuk menentukan perencatan pendhasilan 
NO. 
 
Ekstrak kulit batang G. cowa Roxb didapati mempunyai aktiviti kesitotoksikan yang 
selektif terhadap NCI-H460 (IC50 = 11 µg/mL). Ekstrak ini juga didapati menunjukkan 
aktiviti perencatan produksi NO (IC50 = 25 µg/mL) tanpa menunjukkan kesitotoksikan 
 vii
terhadap sel RAW 264.7. Garcinia cowa Roxb telah dipilih untuk kajian lebih lanjut 
berdasarkan keputusan penilaian aktiviti-aktiviti biologi tersebut. 
Pengasingan dan penulenan ekstrak kulit batang G. cowa berpandukan biocerakin telah 
membawa kepada tujuh penemuan sebatian. Daripada tujuh sebatian tersebut, tiga 
merupakan sebatian baru dan dicirikan sebagai [2E,6E,10E]-(+)-4β-hidroksi-3-metil-5β-
(3,7,11,15-tetrametil-2,6,10,14-heksadecatetraenil-2-sikloheksen-1-on (85), 2-(3-metil-
2-butenil)-1,5,6-trihidroksi-3-metoksi-4-(1,1-dimetil-2-propenil)-9H-xanten-9-on (87) 
and 1,3,6-trihidroksi-7-metoksi-4-(4-asetoksi-3-metil-2-butenil)-8-(3,7-dimetil-2,6-octa 
dienil)xanton (88). Empat sebatian lainnya dicirikan sebagai rubraxanton (5), cowanin 
(52), α-mangostin (81) and 6-hidroksikalabaxanton (86). Tiga sebatian telah diasingkan 
dari daun G. cowa dan dicirikan sebagai metil 2,4,6-trihidroksi-3-(3-metillbut-2-
enil)benzoat (89), garsinisidon-A (90) dan 3-(1-metoksikarbonil-4,6-dihidroksipenoksi)-
6-metoksi-5,5-dimetil-2-butenil)-1,4-benzokuinon (91). Dua dari-  padanya iaitu 
sebatian 89 dan 91 merupakan sebatian baru. Rubraxanton (5) and cowanin (52) telah 
diasingkan kembali bersamaan dengan 1,5-dihiroksixanton (92) dari akar G. cowa.  
 
Sebatian–sebatian tersebut diuji aktiviti sitotoksik mengguakan kaedah mikrotitratan 
(MTT) terhadap sel HL-60, MCF-7, DU-145 adan NCI-H460. Didapati Sebatian 81, 86, 
87, 88, 89, 90 and 91 menunjukkan aktiviti baik hingga tinggi ke atas sel uji. Walaupun 
begitu, sebatian 85 memberikan aktiviti yang selektif kepada NCI-H460 (IC50=16.3 µM 
± 3.0).  
 
 viii
Analisis kitaran sel sebatian 85 terhadap sel NCI-H460 telah dilakukan dengan kaedah 
aliran sitrometri. Sebatian 85 didapati menghambat kitaran sel NCI-H460 pada fasa G1. 
Uji terhadap sebatian 85 dilanjutkan ke kajian in vivo. Menariknya, sebatian ini dapat 
melambatkan selama 5 hari pertumbuhan sel NCI-H460 yang ditanamkan ke tikus 
percubaan, berbanding kawalan.  
 
Rubraxanton (5), α-mangostin (81) dan sebatian 85 dilakukan uji terhadap perencatan 
NO. Rubraxanton (5) menunjukkan perencatan NO dengan nilai peratus 24% dan 77%  
nilai kehidupan sel RAW 264.7. α-Mangostin (81) memberikan nilai peratus perencatan 
NO 83%, dan nilai kehidupan sel RAW masing-masingnya 82%. Perencatan NO oleh 
sebatian 85 memberikan nilai peratus 81% dengan 40% nilai kehidupan sel RAW 264.7.  
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LIST OF ABBREVIATIONS 
 
α  Alpha 
β   Beta 
γ   Gamma 
δ   Delta, chemical shift in ppm 
µg   Microgram 
µl   Microliter 
µM   Micromolar 
br  Broad 
13
C   Carbon-13 
d    Doublet 
dd  Doublet of doublets 
ddd     Doublet of doublets of doublets 
CDK   cyclin dependent kinase 
COSY  Correlation Spectroscopy 
DNA   deoxyribonucleic acid 
DEPT   Distortionless Enhancement by Polarization Transfer 
DMSO  Dimethylsulfoxide 
EIMS  Electron Impact Mass Spectrum 
EtOAc  Ethyl acetate 
eV  Electron volt 
FTIR  Fourier Transform Infra-Red 
